Social Media Ideas for Regn

Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings...

NEW YORK, June 2, 2026 /PRNewswire/ --

Form 13G REGENXBIO Inc. For: 4 June

Apogee Therapeutics: Targeting Atopic Dermatitis

Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

Investors and analysts concluded Regenxbio's positive data was not encouraging enough to pose a competitive threat to the developer of the first marketed DMD gene therapy, Sarepta...

Regency Centers: Above 6.7% From Its Preferred Stocks

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more...